Copyright © 2010 IUPHAR
Annotated and expert reviewed. Please contact us if you can help with updates.
5-HT2B
Previous and Unofficial Names  |
| Names |
References |
| 5-HT2F |
207,214 |
Structural Information  |
|
class A G protein-coupled receptor |
| Species |
TM |
AA |
Chromosomal Location |
Gene Name |
Reference |
| Human |
7 |
481 |
2q36.3-q37.1 |
HTR2B
|
208-210 |
| Rat |
7 |
479 |
9q35 |
Htr2b
|
207 |
| Mouse |
7 |
504 |
1 C5 |
Htr2b
|
211 |
|
|
Database Links  |
|
ChEMBL Target |
227 (Hs), 10021 (Mm), 12688 (Rn) |
|
Ensembl |
ENSG00000135914 (Hs), ENSMUSG00000026228 (Mm), ENSRNOG00000017625 (Rn) |
|
Entrez Gene |
3357 (Hs), 15559 (Mm), 29581 (Rn) |
|
GeneCards |
HTR2B (Hs) |
|
HomoloGene |
55492 (Hs) |
|
OMIM |
601122 (Hs) |
|
PharmGKB Gene |
PA29554 (Hs) |
|
Protein Ontology (PRO) |
PRO:000001167 (Hs) |
|
RefSeq Nucleotide |
NM_000867 (Hs), NM_008311 (Mm), NM_017250 (Rn) |
|
RefSeq Protein |
NP_000858 (Hs), NP_032337 (Mm), NP_058946 (Rn) |
|
UniGene Hs. |
421649 (Hs) |
|
UniProt |
P41595 (Hs), Q02152 (Mm), P30994 (Rn) |
|
Wikipedia |
5-HT2B |
| Search for 3D structures on the PDB |
|
Search using keywords: 5-Hydroxytryptamine receptors 5-HT2B
|
Search using accession numbers: P30994 || P41595 || Q02152
|
| Agonists |
|
Key to terms and symbols
|
View all chemical structures |
Click column headers to sort
|
| Ligand |
|
|
|
|
|
[3H]LSD
|
|
|
|
|
Hs |
Full agonist |
8.7 |
pKd |
202 |
|
methylergonovine
|
|
|
|
|
Hs |
Partial agonist |
9.3 |
pKi |
182,190 |
|
(+)-LSD
|
|
|
|
|
Hs |
Full agonist |
9.0 |
pKi |
182 |
|
cabergoline
|
|
|
|
|
Hs |
Full agonist |
8.9 |
pKi |
69 |
|
ergotamine
|
|
|
|
|
Hs |
Partial agonist |
8.5 – 8.9 |
pKi |
182,190 |
|
methysergide
|
|
|
|
|
Hs |
Partial agonist |
8.0 – 9.4 |
pKi |
182,190,222 |
|
S 16924
|
|
|
|
|
Hs |
Full agonist |
8.4 |
pKi |
66 |
|
AL-37350A
|
|
|
|
|
Hs |
Full agonist |
8.3 |
pKi |
186 |
|
LSD
|
|
|
|
|
Rn |
Full agonist |
8.3 |
pKi |
61 |
|
Ro 60-0175
|
|
|
|
|
Hs |
Full agonist |
8.3 |
pKi |
182 |
|
methysergide
|
|
|
|
|
Rn |
Partial agonist |
8.2 |
pKi |
214 |
|
pergolide
|
|
|
|
|
Hs |
Full agonist |
8.2 |
pKi |
69 |
|
5-HT
|
|
|
|
|
Hs |
Full agonist |
7.9 – 8.4 |
pKi |
182,186,190,209,221 |
|
5-HT
|
|
|
|
|
Rn |
Full agonist |
8.1 |
pKi |
214 |
|
α-methyl-5-HT
|
|
|
|
|
Hs |
Full agonist |
7.9 – 8.3 |
pKi |
182,209,221 |
|
5-HT
|
|
|
|
|
Rn |
Full agonist |
8.0 |
pKi |
214 |
|
5-MeOT
|
|
|
|
|
Rn |
Full agonist |
8.0 |
pKi |
214 |
|
α-methyl-5-HT
|
|
|
|
|
Rn |
Full agonist |
8.0 |
pKi |
214 |
|
(+)-norfenfluramine
|
|
|
|
|
Hs |
Full agonist |
8.0 |
pKi |
190 |
|
BW723C86
|
|
|
|
|
Hs |
Full agonist |
7.3 – 8.6 |
pKi |
182,221,223 |
|
m-CPP
|
|
|
|
|
Hs |
Partial agonist |
7.4 – 8.5 |
pKi |
182,190,192,222-223 |
|
RU 24969
|
|
|
|
|
Rn |
Full agonist |
7.8 |
pKi |
214 |
|
(R)-DOI
|
|
|
|
|
Hs |
Full agonist |
7.7 |
pKi |
186 |
|
DOI
|
|
|
|
|
Hs |
Full agonist |
7.6 – 7.7 |
pKi |
192,209,223 |
|
DOI
|
|
|
|
|
Rn |
Full agonist |
7.6 |
pKi |
209,214 |
|
(+)-DOI
|
|
|
|
|
Hs |
Full agonist |
7.6 |
pKi |
182 |
|
m-CPP
|
|
|
|
|
Rn |
Partial agonist |
7.6 |
pKi |
214 |
|
DOB
|
|
|
|
|
Hs |
Full agonist |
7.4 – 7.6 |
pKi |
182,192 |
|
VER-3323
|
|
|
|
|
Hs |
Full agonist |
7.5 |
pKi |
182 |
|
BRL-15572
|
|
|
|
|
Hs |
Partial agonist |
7.4 |
pKi |
58 |
|
org 37684
|
|
|
|
|
Hs |
Full agonist |
7.4 |
pKi |
182 |
|
(R)-DOI
|
|
|
|
|
Hs |
Full agonist |
7.3 – 7.4 |
pKi |
182,185 |
|
(-)-norfenfluramine
|
|
|
|
|
Hs |
Full agonist |
7.3 |
pKi |
190 |
|
(±)-norfenfluramine
|
|
|
|
|
Hs |
Full agonist |
7.3 |
pKi |
190 |
|
TFMPP
|
|
|
|
|
Hs |
Full agonist |
7.2 |
pKi |
182 |
|
quipazine
|
|
|
|
|
Hs |
Full agonist |
7.1 |
pKi |
182 |
|
TFMPP
|
|
|
|
|
Rn |
Full agonist |
7.1 |
pKi |
214 |
|
org 12962
|
|
|
|
|
Hs |
Full agonist |
7.0 |
pKi |
182 |
|
tryptamine
|
|
|
|
|
Rn |
Full agonist |
7.0 |
pKi |
214 |
|
tryptamine
|
|
|
|
|
Hs |
Full agonist |
7.0 |
pKi |
182 |
|
quipazine
|
|
|
|
|
Rn |
Full agonist |
6.9 |
pKi |
214 |
|
RU 24969
|
|
|
|
|
Hs |
Full agonist |
6.9 |
pKi |
182 |
|
5-CT
|
|
|
|
|
Rn |
Full agonist |
6.8 |
pKi |
209,214 |
|
5-CT
|
|
|
|
|
Hs |
Full agonist |
6.7 – 6.9 |
pKi |
182,209 |
|
2-methyl-5-HT
|
|
|
|
|
Rn |
Full agonist |
6.6 |
pKi |
214 |
|
MK-212
|
|
|
|
|
Hs |
Full agonist |
6.2 – 6.8 |
pKi |
182,223 |
|
MK-212
|
|
|
|
|
Rn |
Full agonist |
6.4 |
pKi |
214 |
|
GR-127935
|
|
|
|
|
Hs |
Partial agonist |
6.2 |
pKi |
58 |
|
CGS-12066
|
|
|
|
|
Hs |
Full agonist |
6.1 |
pKi |
182 |
|
LY344864
|
|
|
|
|
Hs |
Full agonist |
5.8 |
pKi |
64 |
|
SB 216641
|
|
|
|
|
Hs |
Partial agonist |
5.8 |
pKi |
58 |
|
SL65.0155
|
|
|
|
|
Hs |
Partial agonist |
5.8 |
pKi |
67 |
|
quinpirole
|
|
|
|
|
Hs |
Full agonist |
5.0 – 6.5 |
pKi |
69,182 |
|
pindolol
|
|
|
|
|
Hs |
Full agonist |
5.7 |
pKi |
182 |
|
8-OH-DPAT
|
|
|
|
|
Rn |
Full agonist |
5.4 |
pKi |
214 |
|
8-OH-DPAT
|
|
|
|
|
Hs |
Full agonist |
5.4 |
pKi |
182 |
|
| View species-specific agonist tables |
| Agonist Comments |
| Methysergide is a low intrinsic efficacy partial agonist, although in some functional assays it may behave as an antagonist. |
| Antagonists |
|
Key to terms and symbols
|
View all chemical structures |
Click column headers to sort
|
| Ligand |
|
|
|
|
|
[3H]rauwolscine
|
|
|
|
|
Hs |
Antagonist |
8.4 |
pKd |
222 |
|
RS-127445
|
|
|
|
|
Hs |
Antagonist |
9.5 |
pKi |
224 |
|
EGIS-7625
|
|
|
|
|
Hs |
Antagonist |
9.0 |
pKi |
195 |
|
RS-127445
|
|
|
|
|
Hs |
Antagonist |
9.0 |
pKi |
182 |
|
LY53857
|
|
|
|
|
Hs |
Antagonist |
8.8 – 9.1 |
pKi |
222 |
|
methiothepin
|
|
|
|
|
Hs |
Antagonist |
8.7 – 9.2 |
pKi |
182,222 |
|
ritanserin
|
|
|
|
|
Hs |
Antagonist |
8.7 – 9.2 |
pKi |
182,197,222,224 |
|
lisuride
|
|
|
|
|
Hs |
Antagonist |
8.9 |
pKi |
69 |
|
metergoline
|
|
|
|
|
Hs |
Antagonist |
8.8 |
pKi |
182 |
|
1-naphthylpiperazine
|
|
|
|
|
Hs |
Antagonist |
8.4 – 9.0 |
pKi |
209,222 |
|
mesulergine
|
|
|
|
|
Hs |
Antagonist |
8.5 – 8.8 |
pKi |
182,195,222 |
|
SB 221284
|
|
|
|
|
Hs |
Antagonist |
8.6 |
pKi |
182 |
|
clozapine
|
|
|
|
|
Hs |
Antagonist |
8.0 – 8.8 |
pKi |
66,182,222 |
|
tegaserod
|
|
|
|
|
Hs |
Antagonist |
8.4 |
pKi |
221 |
|
1-naphthylpiperazine
|
|
|
|
|
Rn |
Antagonist |
8.3 – 8.4 |
pKi |
209,214 |
|
mianserin
|
|
|
|
|
Hs |
Antagonist |
7.9 – 8.8 |
pKi |
182,222,224 |
|
ritanserin
|
|
|
|
|
Rn |
Antagonist |
8.3 |
pKi |
214 |
|
SB 215505
|
|
|
|
|
Hs |
Antagonist |
8.3 |
pKi |
197 |
|
LY53857
|
|
|
|
|
Rn |
Antagonist |
8.2 |
pKi |
214 |
|
metergoline
|
|
|
|
|
Rn |
Antagonist |
8.2 |
pKi |
214 |
|
terguride
|
|
|
|
|
Hs |
Antagonist |
8.2 |
pKi |
69 |
|
rauwolscine
|
|
|
|
|
Hs |
Antagonist |
7.8 – 8.4 |
pKi |
222 |
|
SB 206553
|
|
|
|
|
Hs |
Antagonist |
7.6 – 8.5 |
pKi |
182,221 |
|
SB 228357
|
|
|
|
|
Hs |
Antagonist |
8.0 – 8.1 |
pKi |
197,200 |
|
amesergide
|
|
|
|
|
Rn |
Antagonist |
8.0 |
pKi |
214 |
|
LY86057
|
|
|
|
|
Rn |
Antagonist |
7.9 |
pKi |
214 |
|
xanomeline
|
|
|
|
|
Hs |
Antagonist |
7.7 |
pKi |
73 |
|
yohimbine
|
|
|
|
|
Hs |
Antagonist |
7.4 – 7.9 |
pKi |
209,222,224 |
|
roxindole
|
|
|
|
|
Hs |
Antagonist |
7.5 |
pKi |
69 |
|
mesulergine
|
|
|
|
|
Rn |
Antagonist |
7.4 |
pKi |
214 |
|
rauwolscine
|
|
|
|
|
Rn |
Antagonist |
7.4 |
pKi |
214 |
|
bromocriptine
|
|
|
|
|
Hs |
Antagonist |
7.3 |
pKi |
69 |
|
mianserin
|
|
|
|
|
Rn |
Antagonist |
7.3 |
pKi |
214 |
|
yohimbine
|
|
|
|
|
Rn |
Antagonist |
7.3 |
pKi |
214 |
|
trazodone
|
|
|
|
|
Hs |
Antagonist |
7.1 |
pKi |
182,190 |
|
SB 243213
|
|
|
|
|
Hs |
Antagonist |
7.0 |
pKi |
200 |
|
apomorphine
|
|
|
|
|
Hs |
Antagonist |
6.9 |
pKi |
69 |
|
SB 204741
|
|
|
|
|
Hs |
Antagonist |
6.9 |
pKi |
182 |
|
SB 242084
|
|
|
|
|
Hs |
Antagonist |
6.8 – 7.0 |
pKi |
182,201 |
|
S33084
|
|
|
|
|
Hs |
Antagonist |
6.8 |
pKi |
75 |
|
SDZ SER-082
|
|
|
|
|
Hs |
Antagonist |
6.7 |
pKi |
182 |
|
agomelatine
|
|
|
|
|
Hs |
Antagonist |
6.6 |
pKi |
203 |
|
piboserod
|
|
|
|
|
Hs |
Antagonist |
6.6 |
pKi |
221 |
|
sarpogrelate
|
|
|
|
|
Hs |
Antagonist |
6.6 |
pKi |
202 |
|
spiroxatrine
|
|
|
|
|
Hs |
Antagonist |
6.3 – 6.8 |
pKi |
222 |
|
ketanserin
|
|
|
|
|
Hs |
Antagonist |
6.1 – 6.7 |
pKi |
182,196,202,209,222 |
|
piboserod
|
|
|
|
|
Hs |
Antagonist |
6.3 |
pKi |
225 |
|
L-741,626
|
|
|
|
|
Hs |
Antagonist |
6.2 |
pKi |
75 |
|
spiperone
|
|
|
|
|
Hs |
Antagonist |
5.9 – 6.5 |
pKi |
182,209,222 |
|
haloperidol
|
|
|
|
|
Hs |
Antagonist |
5.8 – 6.4 |
pKi |
222 |
|
RS-102221
|
|
|
|
|
Hs |
Antagonist |
6.0 – 6.1 |
pKi |
182,198 |
|
AMI-193
|
|
|
|
|
Hs |
Antagonist |
6.0 |
pKi |
182 |
|
MDL-100,907
|
|
|
|
|
Hs |
Antagonist |
6.0 |
pKi |
182,197 |
|
piribedil
|
|
|
|
|
Hs |
Antagonist |
5.9 |
pKi |
69 |
|
SB 224289
|
|
|
|
|
Hs |
Antagonist |
5.9 |
pKi |
182 |
|
SB 277011-A
|
|
|
|
|
Hs |
Antagonist |
5.9 |
pKi |
147 |
|
pindolol
|
|
|
|
|
Hs |
Antagonist |
5.7 |
pKi |
182 |
|
MDL-11,939
|
|
|
|
|
Hs |
Antagonist |
5.5 |
pKi |
182 |
|
spiperone
|
|
|
|
|
Rn |
Antagonist |
5.5 |
pKi |
214 |
|
ketanserin
|
|
|
|
|
Rn |
Antagonist |
5.4 |
pKi |
214 |
|
fluoxetine
|
|
|
|
|
Hs |
Antagonist |
5.3 |
pKi |
190 |
|
norfluoxetine
|
|
|
|
|
Hs |
Antagonist |
5.3 |
pKi |
190 |
|
melatonin
|
|
|
|
|
Hs |
Antagonist |
5.2 |
pKi |
203 |
|
|
View species-specific antagonist tables
|
Primary Transduction Mechanisms
|
| Transducer |
Effector/Response |
|
Gq/G11 family |
|
Tissue Distribution
|
| Uterus, trachea, small intestine > liver, heart, ovary, skeletal muscle, brain, kidney, testis, placenta, prostate, pancreas. |
| Species: |
Human |
| Technique: |
RT-PCR. |
| References: |
209 |
|
|
| Stomach > small intestine, large intestine > heart, lung, kidney, cerebellum > cerebrum. |
| Species: |
Mouse |
| Technique: |
RT-PCR. |
| References: |
218 |
|
|
| Renal artery. |
| Species: |
Rat |
| Technique: |
Western blotting and immunohistochemistry. |
| References: |
173 |
|
|
| Thymus, peripheral blood lymphocytes, spleen, mitogen-activated spleen cells. |
| Species: |
Rat |
| Technique: |
RT-PCR. |
| References: |
116 |
|
|
Functional Assays
|
| Measurement of IP and IP3 levels in AV12 cells transfected with the rat 5-HT2B receptor. |
| Species: |
Rat |
| Tissue: |
AV12 cells. |
| Response measured: |
IP and IP3 production. |
| References: |
167 |
|
|
| Measurement of intracellular Ca2+ levels using a fluorometric imaging plate reader (FLIPR) in CHO-K1 cells transfected with the human 5-HT2B receptor. |
| Species: |
Human |
| Tissue: |
CHO-K1 cells. |
| Response measured: |
Increase in intracellular [Ca2+]. |
| References: |
168 |
|
|
Physiological Functions
|
| Contraction. |
| Species: |
Rat |
| Tissue: |
Stomach fundus. |
| References: |
219 |
|
|
| Endothelium-dependent relaxation. |
| Species: |
Rat |
| Tissue: |
Jugular vein. |
| References: |
220 |
|
|
| Regulation of the differentiation and proliferation of the developing and adult heart. |
| Species: |
Mouse |
| Tissue: |
In vivo. |
| References: |
215-216 |
|
|
Physiological Consequences of Altering Gene Expression
|
| 5-HT2B receptor knockout mice exhibit gross heart defects. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
215-216 |
|
|
| Overexpression of the 5-HT2B receptor in the heart causes mitochondrial proliferation leading to ventricular hypertrophy. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Transgenesis. |
| References: |
217 |
|
|
To cite this receptor data page, please use the following:
Rodrigo Andrade, Nicholas M. Barnes, Gordon Baxter, Joel Bockaert, Theresa Branchek, Marlene L. Cohen, Aline Dumuis, Richard M. Eglen, Manfred Göthert, Mark Hamblin, Michel Hamon, Paul R. Hartig, René Hen, Katharine Herrick-Davis, Rebecca Hills, Daniel Hoyer, Patrick P. A. Humphrey, Klaus Peter Latté, Luc Maroteaux, Graeme R. Martin, Derek N. Middlemiss, Ewan Mylecharane, Stephen J. Peroutka, Pramod R. Saxena, Andrew Sleight, Carlos M. Villalon, Frank Yocca.
5-Hydroxytryptamine receptors: 5-HT2B. Last modified on 2010-06-28. Accessed on 2010-09-03. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=7.
Contact us | Print | Back to top | Help